Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EyePoint, Inc. (EYPT) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, offering detailed insight into this clinical-stage biopharmaceutical company focused on serious retinal diseases. EyePoint’s filings, including multiple Form 8-K reports, document material events such as clinical milestones, equity offerings, and corporate actions related to its lead investigational product, DURAVYU™ (vorolanib intravitreal insert).
Through these filings, investors can review clinical development updates formally reported to the SEC, such as the completion of enrollment in the pivotal Phase 3 LUGANO and LUCIA trials in wet age-related macular degeneration, positive recommendations from the independent Data Safety Monitoring Committee, and the announcement of a pivotal Phase 3 program in diabetic macular edema (COMO and CAPRI). Filings also reference the posting of investor presentations that summarize estimated cash and investments and outline EyePoint’s development plans.
EyePoint’s SEC documents further detail capital markets activity, including an underwriting agreement and public offering of common stock and pre-funded warrants, as well as a Controlled Equity Offering Sales Agreement for at-the-market issuances. These filings describe the terms of offerings, net proceeds, intended use of funds to advance DURAVYU in wet AMD and DME, and the legal opinions related to the validity of issued securities.
Additional filings cover corporate governance and compensation matters, such as amendments to the 2023 Long-Term Incentive Plan, inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4), and the results of stockholder votes at the annual meeting. Risk factors and forward-looking statement sections referenced in filings highlight regulatory interactions, including an FDA warning letter pertaining to EyePoint’s Watertown manufacturing facility and an August 2022 subpoena from the U.S. Attorney’s Office for the District of Massachusetts.
On Stock Titan, EyePoint’s SEC filings are paired with AI-powered summaries that help explain the significance of each document, from 8-K current reports to registration-related filings. This allows readers to quickly understand how new offerings, clinical disclosures, or governance changes may relate to EyePoint’s development of DURAVYU and its broader ophthalmic pipeline, while still having direct access to the full text of each filing as made available through EDGAR.
EYPT related Form 144: reported planned sale of 9,750 shares and recent 10b5-1 dispositions. The filing states 9,750 shares of Common stock are to be sold on 04/17/2026 in connection with an exercise of stock options for cash. It also lists prior 10b5-1 sales by Ramiro Ribeiro of 2,438 shares on 03/04/2026 (proceeds $43,571.69) and 2,437 shares on 02/17/2026 (proceeds $36,555.00).
EyePoint, Inc. filed an 8-K to share an updated investor presentation focused on DURAVYU, its sustained-release tyrosine kinase inhibitor for retinal disease. The deck highlights Phase 3 programs in wet age-related macular degeneration and diabetic macular edema, with topline wet AMD data expected beginning in mid-2026.
EyePoint reports approximately $220 million in cash and investments as of March 31, 2026, which it believes supports its operating runway into the fourth quarter of 2027. Phase 3 wet AMD trials LUGANO and LUCIA are fully enrolled at roughly 400 patients each, while Phase 3 DME trials COMO and CAPRI target about 240 patients each with full enrollment anticipated in the third quarter of 2026. The company is also scaling a 41,000 square-foot commercial manufacturing facility in Northbridge, Massachusetts to support a potential New Drug Application filing and commercialization of DURAVYU.
The Vanguard Group filed an amendment on a Schedule 13G/A reporting zero shares beneficially owned of EyePoint Inc Common Stock and 0% of the class. The amendment states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries and business divisions will report beneficial ownership separately and Vanguard no longer is deemed to beneficially own those securities. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
EyePoint, Inc. President and CEO Jay S. Duker restructured his holdings by selling shares and stock options to a family trust. On March 23, 2026, he sold 76,766 shares of Common Stock and options over an additional 150,000 shares to the Duker Family 2024 Irrevocable Trust in exchange for a promissory note of $2,398,220.93, reflecting the fair market value of the securities. After the transactions, he continued to hold some Common Stock and options directly, while the Family Trust held the transferred positions. The securities in the Family Trust are for the benefit of his children, his spouse serves as trustee, and he disclaims beneficial ownership of those trust-held securities.
EyePoint, Inc. reported an insider-related purchase involving a family trust associated with President and CEO Jay S. Duker. The trust bought 1,500 shares of common stock in an open-market transaction at $13.1492 per share.
After this trade, the family trust holds 100,665 shares of EyePoint common stock, while Duker directly owns 77,752 shares. The shares in the trust are for the benefit of his children, with his spouse serving as trustee, and Duker disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. Chief Financial Officer George Elston reported non-sale insider transactions involving company common stock. On March 2, 2026, he made bona fide gift transfers totaling 10,000 shares, with 5,000 shares from his directly held stock and 5,000 shares from stock reported as indirectly held.
Footnotes explain that some shares were transferred to an irrevocable family trust for the benefit of his immediate family, with JP Morgan Trust Company of Delaware as trustee. The filing states that he disclaims beneficial ownership of the securities held in the family trust.
EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on serious retinal diseases using its Durasert E™ sustained drug delivery technology. Its lead candidate, DURAVYU™ (vorolanib in Durasert E), is in global Phase 3 trials for wet age-related macular degeneration and diabetic macular edema.
The company reports cash, cash equivalents and marketable securities of $306.1 million as of December 31, 2025, which it believes will fund operations into the fourth quarter of 2027, beyond expected Phase 3 wet AMD topline data in 2026. DURAVYU has shown favorable safety and efficacy in Phase 1 and 2 trials and is licensed regionally through Equinox/Betta.
EyePoint highlights extensive risk factors, including reliance on DURAVYU’s clinical and commercial success, the need for additional capital, an ongoing DOJ investigation related to historical DEXYCU® practices, and an FDA warning letter regarding YUTIQ® manufacturing that it states has been addressed with corrective actions. The company operates manufacturing facilities in Watertown and Northbridge, Massachusetts and employed 214 people as of February 27, 2026.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported insider transactions involving stock options and common shares. On March 4, 2026, he exercised a stock option covering 2,438 shares of common stock at an exercise price of $8.2600 per share and reported acquiring the corresponding common shares. He then sold 2,438 shares of common stock in open-market transactions at a weighted average price of $17.8719 per share, with individual sale prices ranging from $17.22 to $18.45. A separate option grant is disclosed as vesting 25% on January 3, 2026, with the remainder vesting monthly over the following three years.
EyePoint, Inc. reported weaker fourth-quarter and full-year 2025 results as it increased investment in its lead retinal drug candidate, DURAVYU. For 2025, total net revenue was $31.4 million versus $43.3 million in 2024, while operating expenses rose to $274.8 million from $189.1 million, driven mainly by Phase 3 trials in wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
The company’s 2025 net loss widened to $232.0 million, or $3.17 per share, compared with a $130.9 million loss, or $2.32 per share, in 2024. Cash, cash equivalents and marketable securities totaled $306 million as of December 31, 2025, and EyePoint expects this to fund operations into the fourth quarter of 2027, through key Phase 3 milestones for DURAVYU.
Both pivotal Phase 3 DURAVYU trials in wet AMD (LUGANO and LUCIA, enrolling over 900 patients) remain on track for topline data beginning in mid-2026, with a data safety committee recommending continuation without changes. Phase 3 COMO and CAPRI trials in DME have begun dosing patients, with topline data expected in the second half of 2027, underscoring management’s focus on regulatory and commercial readiness for potential future launch.